NCT00343980 - Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes | Biotech Hunter

Enrollment

363

Participants

Timeline

Start Date

October 10, 2006

Primary Completion Date

March 10, 2008

Study Completion Date

March 10, 2008

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

rosiglitazone

Tablets, 4 mg once or twice a day.

DRUG

inhaled human insulin

Treat-to-target dose titration scheme, pre-prandial, inhalation.

DRUG

glimepiride

Tablets, 4 mg/day.

Trial Locations (26)

1000

Novo Nordisk Investigational Site, Skopje

Novo Nordisk Investigational Site, Manila

1200

Novo Nordisk Investigational Site, Makati City

2065

Novo Nordisk Investigational Site, St Leonards

2500

Novo Nordisk Investigational Site, Wollongong

2605

Novo Nordisk Investigational Site, Garran

2747

Novo Nordisk Investigational Site, Kingswood

6000

Novo Nordisk Investigational Site, Cebu City

16059

Novo Nordisk Investigational Site, Bursa

34098

Novo Nordisk Investigational Site, Istanbul

34390

Novo Nordisk Investigational Site, Istanbul

34718

Novo Nordisk Investigational Site, Istanbul

35100

Novo Nordisk Investigational Site, Bornova-IZMIR

119034

Novo Nordisk Investigational Site, Moscow

121356

Novo Nordisk Investigational Site, Moscow

127486

Novo Nordisk Investigational Site, Moscow

127644

Novo Nordisk Investigational Site, Moscow

194354

Novo Nordisk Investigational Site, Saint Petersburg

198013

Novo Nordisk Investigational Site, Saint Petersburg

560010

Novo Nordisk Investigational Site, Bangalore

600020

Novo Nordisk Investigational Site, Chennai

600086

Novo Nordisk Investigational Site, Chennai

632004

Novo Nordisk Investigational Site, Vellore

641002

Novo Nordisk Investigational Site, Coimbatore

31 000

Novo Nordisk Investigational Site, Osijek

10 000

Novo Nordisk Investigational Site, Zagreb